(Q53547764)

15 May 2018

title

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. (English)

1 reference

15 May 2018

1 reference

8

Ulrich M Zanger

1 reference

15 May 2018

David Flockhart

7

object named as

David A Flockhart

1 reference

15 May 2018

Zeruesenay Desta

1

object named as

Zeruesenay Desta

1 reference

15 May 2018

author name string

Tanja Saussele

2

1 reference

15 May 2018

Bryan Ward

3

1 reference

15 May 2018

Julia Blievernicht

4

1 reference

15 May 2018

Lang Li

5

1 reference

15 May 2018

Kathrin Klein

6

1 reference

15 May 2018

publication date

1 June 2007

1 reference

15 May 2018

published in

Pharmacogenomics

1 reference

15 May 2018

volume

8

1 reference

15 May 2018

issue

6

1 reference

15 May 2018

page(s)

547-558

1 reference

15 May 2018

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Functional characterization of cytochrome P450 2B6 allelic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Three haplotypes associated with CYP2A6 phenotypes in Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Haplotype structure and allele frequencies of CYP2B6 in a Korean population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

Sex is a major determinant of CYP3A4 expression in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.547

21 January 2018

Identifiers

DOI

10.2217/14622416.8.6.547

1 reference

15 May 2018

1 reference

15 May 2018